Therapeutic targets for Gaucher's disease

Drugs of the Future

Volumn 34, Issue 12, 2009, Pages 1001-1004

  Sorbera, L A ^a   Sundaravinayagam, D ^a   Dulsat, C ^a   Rosa, E ^a  

^a THOMSON REUTERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; CHAPERONE; EXR 202; GENZ 112638; ISOFAGOMINE TARTRATE; MIGLUSTAT; PEG GLUCOCEREBROSIDASE; TALIGLUCERASE ALFA; UNCLASSIFIED DRUG; VELAGLUCERASE ALPHA;

ARTICLE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME REPLACEMENT; ENZYME SUBSTRATE; ENZYME SYNTHESIS; GAUCHER DISEASE; HOMEOSTASIS; HUMAN; NONHUMAN;

EID: 84930542337     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.12.1444443     Document Type: Article

References (21)

1. Prous Science Integrity Disease Briefings: Gaucher's Disease (online publication). Updated 2010.
2. Butters, T.D. Gaucher disease. Curr Opin Chem Biol 2007, 11(4): 412-418
3. Guggenbuhl, P., Grosbois, B., Chalès, G. Gaucher disease. Joint Bone Spine 2008, 75(2): 116-124
4. Zeller, J.L., Burke, A.E., Glass, R.M. JAMA patient page. Gaucher disease. JAMA 2007, 298(11): 1358.
5. Martins, A.M., Valadares, E.R., Porta, G. et al. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr 2009, 155(4, Suppl.): S10-8.
6. Hollak, C.E., de Fost, M., van Dussen, L., Vom Dahl, S., Aerts, J.M. Enzyme therapy for the treatment of type 1 Gaucher disease: Clinical outcomes and dose-response relationships. Expert Opin Pharmacother 2009, 10(16): 2641-2652
7. Lim-Melia, E.R., Kronn, D.F. Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann 2009, 38(8): 448-55.
8. Jakóbkiewicz-Banecka, J., Wegrzyn, A., Wegrzyn, G. Substrate deprivation therapy: A new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J Appl Genet 2007, 48(4): 383-388 (Pubitemid 350219938)
9. Harmanci, O., Bayraktar, Y. Gaucher disease: New developments in treatment and etiology. World J Gastroenterol 2008, 14(25): 3968-3973
10. Wennekes, T., van den Berg, R.J., Boot, R.G., van der Marel, G.A., Overkleeft, H.S., Aerts, J.M. Glycosphingolipids-Nature, function, and pharmacological modulation. Angew Chem lnt Ed Engl 2009, 48(47): 8848-8869
11. Gupta, V., Patwardhan, G.A., Zhang, Q.J., Cabot, M.C., Jazwinski, S.M., Liu, Y.Y. Direct quantitative determination of ceramide glycosylation in vivo: A new approach to evaluate cellular enzyme activity of glucosylceramide synthase (GIcT-1). J Lipid Res, Epub ahead of print.
12. Townson, K.H., Speak, A.O., Greenshields, K.N., Goodyear, C.S, Willison, H.J, Platt, F.M. Glycosphingolipid depletion in PC12 cells using iminosugars protects neuronal membranes from anti-ganglioside antibody mediated injury. J Neuroimmunol 2008, 203(1): 33-38
13. Luan, Z., Higaki, K., Aguilar-Moncayo, M., Ninomiya, H. et al. Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin. Chembiochem 2009, 10(17): 2780-2792
14. Sánchez-Ollé, G., Duque, J., Egido-Gabás, M., Casas, J., Lluch, M., Chabés, A., Grinberg, D., Vilageliu, L. Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease. Blood Cells Mol Dis 2009, 42(2): 159-166
15. Elleder, M. Glucosylceramide transfer from lysosomes-The missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data. J Inherit Metab Dis 2006, 29(6): 707-715
16. Enquist, I.B., Nilsson, E., Ooka, A. et al. Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci USA 2006, 103(37): 13819-13824 (Pubitemid 44413991)
17. Lieberman, R.L., D'aquino, J.A., Ringe, D., Petsko, G.A. Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry 2009, 48(22): 4816-4827
18. Voss, A.A., Díez-Sampedro, A., Hirayama, B.A., Loo, D.D., Wright, E.M. Imino sugars are potent agonists of the human glucose sensor SGLT3. Mol Pharmacol 2007, 71(2): 628-634 (Pubitemid 46147927)
19. Lachmann, R.H. Miglustat: Substrate reduction therapy for glycosphingolipid lysosomal storage disorders. Drugs Today (Barc) 2006, 42(1): 29-38.
20. Brady, R.O. Emerging strategies for the treatment of hereditary metabolic storage disorders. Rejuvenation Res 2006, 9(2): 237-244
21. Weinreb, N.J., Barranger, J.A., Charrow, J., Grabowski, G.A., Mankin, H.J., Mistry, P. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 2005, 80(3): 223-229 (Pubitemid 41579546)